Free Access
Med Sci (Paris)
Volume 34, October 2018
Cancer biomarkers
Page(s) 81 - 86
Published online 07 November 2018
  1. Collins M Wilhelm M Conyers R et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 ; 31 : 2303–2312. [CrossRef] [PubMed] [Google Scholar]
  2. Hasei J Sasaki T Tazawa H et al. Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells. Molecular cancer therapeutics 2013 ; 12 : 314–325. [CrossRef] [PubMed] [Google Scholar]
  3. Mirabello L Troisi RJ Savage SA Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 2009 ; 115 : 1531–1543. [CrossRef] [PubMed] [Google Scholar]
  4. Zhou W Hao M Du X et al. Advances in targeted therapy for osteosarcoma. Discovery medicine 2014 ; 17 : 301–307. [PubMed] [Google Scholar]
  5. Sakamoto A Iwamoto Y Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Reviews on recent clinical trials 2008 ; 3 : 228–231. [CrossRef] [PubMed] [Google Scholar]
  6. Glisovic T Bachorik JL Yong J Dreyfuss G RNA-binding proteins and post-transcriptional gene regulation. FEBS letters 2008 ; 582 : 1977–1986. [CrossRef] [PubMed] [Google Scholar]
  7. Nagase T, Seki N, Tanaka A, et al. Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of cDNA clones from human cell line KG-1. DNA research : an international journal for rapid publication of reports on genes and genomes 1995; 2 : 167–74, 99–210. [CrossRef] [PubMed] [Google Scholar]
  8. Bechara Elias G, Sebestyén E, Bernardis I, et al. RBM5, 6, and 10 Differentially Regulate NUMB Alternative Splicing to Control Cancer Cell Proliferation. Molecular Cell 2013; 52 : 720–33. [Google Scholar]
  9. Wang Y Gogol-Doring A Hu H et al. Integrative analysis revealed the molecular mechanism underlying RBM10-mediated splicing regulation. EMBO molecular medicine 2013 ; 5 : 1431–1442. [CrossRef] [PubMed] [Google Scholar]
  10. Zheng S Damoiseaux R Chen L Black DL A broadly applicable high-throughput screening strategy identifies new regulators of Dlg4 (Psd-95) alternative splicing. Genome research 2013 ; 23 : 998–1007. [CrossRef] [PubMed] [Google Scholar]
  11. Inoue A Yamamoto N Kimura M et al. RBM10 regulates alternative splicing. FEBS letters 2014 ; 588 : 942–947. [CrossRef] [PubMed] [Google Scholar]
  12. Hernandez J Bechara E Schlesinger D et al. Tumor suppressor properties of the splicing regulatory factor RBM10. RNA biology 2016 ; 13 : 466–472. [CrossRef] [PubMed] [Google Scholar]
  13. Atsumi T Suzuki H Jiang JJ et al. Rbm10 regulates inflammation development via alternative splicing of Dnmt3b. International immunology 2017 ; 29 : 581–591. [CrossRef] [PubMed] [Google Scholar]
  14. Sutherland LC Thibault P Durand M et al. Splicing arrays reveal novel RBM10 targets, including SMN2 pre-mRNA. BMC molecular biology 2017 ; 18 : 19. [CrossRef] [PubMed] [Google Scholar]
  15. Vinayanuwattikun C Le Calvez-Kelm F Abedi-Ardekani B et al. Elucidating Genomic Characteristics of Lung Cancer Progression from In Situ to Invasive Adenocarcinoma. Scientific reports 2016 ; 6 : 31628. [CrossRef] [PubMed] [Google Scholar]
  16. Imielinski M Berger AH Hammerman PS et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012 ; 150 : 1107–1120. [CrossRef] [PubMed] [Google Scholar]
  17. Sebestyen E Singh B Minana B et al. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome research 2016 ; 26 : 732–744. [CrossRef] [PubMed] [Google Scholar]
  18. Giannakis M Mu XJ Shukla SA et al. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell reports 2016 ; 15 : 857–865. [CrossRef] [PubMed] [Google Scholar]
  19. Furukawa T Kuboki Y Tanji E et al. Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas. Scientific reports 2011 ; 1 : 161. [CrossRef] [PubMed] [Google Scholar]
  20. Witkiewicz AK McMillan EA Balaji U et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nature communications 2015 ; 6 : 6744. [CrossRef] [PubMed] [Google Scholar]
  21. Ibrahimpasic T Xu B Landa I et al. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of MED12 and RBM10 as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clinical cancer research : an official journal of the American Association for Cancer Research 2017 ; 23 : 5970–5980. [CrossRef] [PubMed] [Google Scholar]
  22. Lukong KE Chang KW Khandjian EW Richard S RNA-binding proteins in human genetic disease. Trends in genetics : TIG 2008 ; 24 : 416–425. [CrossRef] [PubMed] [Google Scholar]
  23. Guan G Li R Tang W et al. Expression of RNA-binding motif 10 is associated with advanced tumor stage and malignant behaviors of lung adenocarcinoma cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2017 ; 39 : 1010428317691740. [PubMed] [Google Scholar]
  24. Wang K Bacon ML Tessier JJ et al. RBM10 Modulates Apoptosis and Influences TNF-alpha Gene Expression. Journal of cell death 2012 ; 5 : 1–19. [PubMed] [Google Scholar]
  25. Zhao J Sun Y Huang Y et al. Functional analysis reveals that RBM10 mutations contribute to lung adenocarcinoma pathogenesis by deregulating splicing. Scientific reports 2017 ; 7 : 40488. [CrossRef] [PubMed] [Google Scholar]
  26. Loiselle JJ Roy JG Sutherland LC RBM10 promotes transformation-associated processes in small cell lung cancer and is directly regulated by RBM5. PloS one 2017 ; 12 : e0180258. [CrossRef] [PubMed] [Google Scholar]
  27. Steeg PS Tumor metastasis: mechanistic insights and clinical challenges. Nature medicine 2006 ; 12 : 895–904. [CrossRef] [PubMed] [Google Scholar]
  28. Chambers AF Groom AC MacDonald IC Dissemination and growth of cancer cells in metastatic sites. Nature reviews Cancer 2002 ; 2 : 563–572. [CrossRef] [PubMed] [Google Scholar]
  29. Rotem A Janzer A Izar B et al. Alternative to the soft-agar assay that permits high-throughput drug and genetic screens for cellular transformation. Proceedings of the National Academy of Sciences of the United States of America 2015 ; 112 : 5708–5713. [CrossRef] [PubMed] [Google Scholar]
  30. Ji Y Xie S Jiang L et al. Increased cell apoptosis in human lung adenocarcinoma and in vivo tumor growth inhibition by RBM10, a tumor suppressor gene. Oncology letters 2017 ; 14 : 4663–4669. [CrossRef] [PubMed] [Google Scholar]
  31. Bechara EG Sebestyen E Bernardis I et al. RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol Cell 2013 ; 52 : 720–733. [CrossRef] [PubMed] [Google Scholar]
  32. James CG Ulici V Tuckermann J et al. Expression profiling of Dexamethasone-treated primary chondrocytes identifies targets of glucocorticoid signalling in endochondral bone development. BMC genomics 2007 ; 8 : 205. [CrossRef] [PubMed] [Google Scholar]
  33. Kiraz Y Adan A Kartal Yandim M, Baran Y. Major apoptotic mechanisms and genes involved in apoptosis. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 ; 37 : 8471–8486. [CrossRef] [PubMed] [Google Scholar]
  34. Martinez-Arribas F Agudo D Pollan M et al. Positive correlation between the expression of X-chromosome RBM genes (RBMX, RBM3, RBM10) and the proapoptotic Bax gene in human breast cancer. Journal of cellular biochemistry 2006 ; 97 : 1275–1282. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.